Aclaris therapeutics, inc. (ACRS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-139,375

-161,354

-181,311

-158,732

-140,074

-132,738

-117,121

-102,573

-86,193

-68,523

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30,979

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

4,759

6,409

7,047

5,799

3,883

1,879

1,102

834

574

402

0

0

0

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

108

-

0

0

0

Stock-based compensation expense

14,768

16,177

17,952

19,339

19,774

20,055

19,399

18,365

16,420

14,430

12,040

9,985

8,035

6,104

4,842

3,382

2,070

891

0

0

0

Change in fair value of contingent consideration

0

-

-

-

-

1,272

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash charges related to Vixen acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

2,784

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-14,884

809

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-1,177

-2,628

-6,699

412

-727

40

3,436

-1,936

687

4,306

4,449

3,935

2,676

8

395

852

572

1,269

0

0

0

Accounts payable

-7,280

-3,160

4,082

1,688

6,451

6,964

7,366

6,096

4,049

4,564

4,025

2,478

633

1,810

1,047

2,582

1,264

-359

0

0

0

Accrued expenses

-8,263

-1,967

10,746

19,043

14,527

6,792

3,484

3,411

2,932

607

446

-71

874

2,450

1,970

1,627

575

552

0

0

0

Net cash used in operating activities

-71,932

-96,445

-103,303

-109,802

-110,257

-100,811

-91,773

-75,629

-63,876

-54,663

0

0

0

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24,461

-

0

0

0

Purchases of property and equipment

1,453

1,613

1,493

1,231

1,342

1,356

1,787

1,497

1,338

1,235

720

514

387

232

302

371

470

507

0

0

0

Purchases of marketable securities

73,154

137,385

170,557

176,759

199,084

161,598

189,185

230,049

215,793

197,337

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of marketable securities

151,426

210,491

217,907

212,568

229,338

239,443

249,280

249,250

221,323

152,527

133,935

103,315

100,188

87,093

49,987

31,602

15,461

6,069

0

0

0

Net cash provided by (used in) investing activities

111,005

105,679

-21,265

-32,544

-38,210

9,367

58,308

8,057

-5,455

-55,692

0

0

0

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from debt financing, net of issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Finance lease payments

460

523

541

553

732

648

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-67,522

-

0

0

0

Proceeds from the issuance of stock

0

-

-

-

-

577

577

394

420

235

0

0

0

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash (used in) provided by financing activities

-19,278

-30,316

127,876

127,965

127,783

128,261

0

80,899

100,535

100,386

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

19,795

-21,082

3,308

-14,381

-20,684

36,817

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

10,546

-

-7,623

21,962

4,662

-906

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable

116

124

266

111

-25

161

356

526

393

274

18

183

62

11

0

0

0

-

-

-

-

Fair value of stock issued in connection with Confluence acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Offering costs included in accounts payable

0

-

-

-

-

210

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease asset recorded as a result of new accounting standard

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,764

0

0

0